Patent royalties are usually calculated as a negotiated percentage of the licensee’s net sales, most often in the 2% to 6% range, though fixed per-unit fees and one-time lump-sum payments are also common. Every element of the calculation, from what counts as “net sales” to when payment is due, is set by the license agreement between the patent holder and the licensee. For tax purposes, the payments are deductible to the licensee as a business expense and taxable to the licensor either as passive royalty income or as self-employment income, depending on how actively the licensor manages the license.
How the Royalty Gets Calculated
The most widespread approach ties the royalty to a percentage of the licensee’s revenue from the patented product. That makes the definition of “net sales” the single most important number in the contract. Net sales typically means gross revenue minus deductions for returns, sales tax, shipping costs, and documented allowances. If the base is defined as gross sales instead of net sales, the licensee’s payment obligation is meaningfully larger for the same headline rate.
Typical rates cluster by industry. Medical device and pharmaceutical patents tend to see rates in the 2% to 5% range, while chemical patents often land between 3% and 6%. Rates above 5% are less common outside industries where a single patent drives most of the product’s value. The widely cited “2% to 10%” range overstates what most licensees actually pay; the high end usually involves exclusive licenses for breakthrough technology with limited alternatives.
License type shapes the rate too. A non-exclusive license, where the patent holder can sign the same rights to multiple companies, generally carries a lower rate because licensees share the market. An exclusive license, which locks out even the patent holder, commands the highest rates. A sole license sits in between: one outside licensee plus the patent holder, and no one else.
The Main Payment Structures
Most agreements use one of four structures, and some combine them.
Percentage of Net Sales
The running royalty on net sales is the default in most industries. It scales with the licensee’s actual commercial success, which both sides can usually accept as fair.
Fixed Fee Per Unit
Some agreements charge a flat dollar amount for every unit the licensee sells or manufactures. This works well when the patented technology is a discrete component inside a larger product. A license for a specific sensor design, for example, might require $0.75 per finished device shipped. Per-unit fees eliminate the complexity of auditing net sales calculations, which is why licensees sometimes prefer them.
Lump-Sum Payment
A lump-sum (or “paid-up”) royalty is a single fixed payment that covers the entire license term. The licensee pays once, up front or on a set schedule, and owes nothing more regardless of unit volume. Parties typically arrive at the amount by projecting sales over the license term and calculating what a running royalty would have produced. The licensor gets certainty and immediate cash; the licensee eliminates ongoing reporting and the risk of rising royalty costs if sales exceed projections.
Minimum Royalties, Tiered Rates, and Caps
Many agreements include a minimum annual royalty, a guaranteed floor the licensee must pay even if sales are slow. This protects the licensor from signing an exclusive license only to watch the licensee sit on the technology. Minimum payments are usually creditable against earned royalties for the same period, so a licensee that exceeds the minimum pays only the earned amount.
Tiered structures adjust the rate at sales thresholds. A contract might set a 5% rate on the first $5 million in annual net sales and drop to 4% on sales between $5 million and $15 million. Some agreements also set a ceiling on total royalties, either annually or over the life of the deal. Annual caps often include a “no carryover” provision, so unused cap room from one year doesn’t roll into the next, and overage above the cap is simply forgiven.
What Sets the Rate
Two approaches dominate private negotiations, and a third is imposed by courts in infringement disputes.
The most common starting point is comparable licenses: what have licensees paid for similar technology in the same industry? If three comparable licenses for related semiconductor patents all fell between 2% and 3.5%, that range anchors the negotiation. The difficulty is finding truly comparable deals, since most license agreements are confidential. Publicly available data tends to come from SEC filings, litigation discovery, and industry surveys.
An income-based approach projects the additional profit the licensee will earn specifically because of the patented feature, then splits that profit between licensor and licensee. It demands detailed modeling to isolate the patent’s contribution from brand, distribution, and unpatented features, but it produces a rate tied to actual economic value rather than industry convention.
When a court must determine a “reasonable royalty” in an infringement case, it applies the 15-factor framework from Georgia-Pacific Corp. v. United States Plywood Corp. Among the most influential factors are the royalties the patent holder has received in prior licenses, rates paid for comparable patents, the established profitability of the patented product, the patent’s remaining term, and the portion of profit attributable to the patented feature versus unpatented elements. Even outside litigation, walking through the Georgia-Pacific factors forces both sides to confront the patent’s actual economic value rather than anchoring on a number pulled from an unrelated deal.
How the Licensor Reports Royalty Income
Where royalty income lands on a tax return depends on how involved the licensor is in the licensing activity. An individual who holds a patent and passively collects royalties reports that income on Schedule E of Form 1040.1Internal Revenue Service. About Schedule E (Form 1040), Supplemental Income and Loss If the licensor is in business as a self-employed inventor who actively manages the licensing program, the IRS directs that income to Schedule C instead, where it is subject to self-employment tax.2Internal Revenue Service. 2025 Instructions for Schedule E (Form 1040) The financial difference is significant: self-employment tax adds roughly 15.3% on top of regular income tax. Corporate licensors report royalty income on their corporate returns.
Timing depends on accounting method. Cash-basis taxpayers report income when they actually receive payment. Accrual-basis taxpayers report it when they earn the right to payment, even if the check hasn’t arrived. Most individual taxpayers use the cash method unless they’ve specifically elected otherwise.
How the Licensee Deducts Royalty Payments
Royalty payments are deductible as ordinary and necessary business expenses. The federal statute allows a deduction for “rentals or other payments required to be made as a condition to the continued use or possession… of property to which the taxpayer has not taken or is not taking title.”3Office of the Law Revision Counsel. 26 USC 162 – Trade or Business Expenses Patent royalties fit squarely within that language.
Classification matters. If the patented technology is integral to manufacturing the product, the royalty typically belongs in cost of goods sold. If it’s used in a more general business capacity, it goes into operating expenses. The distinction affects gross margin reporting and, in some cases, the timing of the deduction relative to inventory turnover.
Withholding on Payments to Foreign Patent Holders
When a U.S. licensee pays royalties to a foreign patent holder, the default rule requires the licensee to withhold 30% of the gross payment and remit it to the IRS.4Office of the Law Revision Counsel. 26 US Code 1441 – Withholding of Tax on Nonresident Aliens Royalties fall within the category of “fixed or determinable annual or periodical” U.S.-source income.
Bilateral tax treaties between the U.S. and the foreign licensor’s home country often reduce or eliminate that 30% rate.5Internal Revenue Service. NRA Withholding To claim the reduced rate, the foreign licensor must give the U.S. licensee a completed IRS Form W-8BEN before the first payment. The form identifies the applicable treaty and the specific article that provides the reduced rate, and if the treaty sets different rates for different types of royalties, the form must specify which type applies.6Internal Revenue Service. Instructions for Form W-8BEN Without a valid W-8BEN on file, the licensee is legally required to withhold at the full 30% rate, regardless of any treaty that might otherwise apply.
The Limit on Post-Expiration Royalties
A patent gives its holder the right to stop others from making, using, or selling the invention for a limited time. For utility and plant patents, the term is generally 20 years from the application filing date.7United States Patent and Trademark Office. Managing a Patent Once the patent expires, the licensor cannot keep collecting royalties for use of the invention. The Supreme Court held in Brulotte v. Thys Co. that post-expiration royalties are unenforceable, and it reaffirmed that rule in 2015 in Kimble v. Marvel Entertainment, calling such provisions “unlawful per se” because they extend the patent monopoly into what should be the public domain.8Justia Law. Kimble v. Marvel Entertainment, LLC, 576 US 446 (2015)
The rule has workarounds the Court itself endorsed. A licensee can defer payments for pre-expiration use into the post-expiration period, effectively amortizing the royalty obligation over a longer timeline. If the license covers multiple patents, royalties can run until the last patent in the bundle expires. And if the license also covers a non-patent right such as a trade secret, the parties can set a reduced royalty rate for the post-expiration period that compensates only for the trade secret.8Justia Law. Kimble v. Marvel Entertainment, LLC, 576 US 446 (2015) Getting this language right at the drafting stage is far cheaper than fixing it after the fact.